One of the great things about equity markets is that you don't need a fortune to get started. Though strong companies that perform well tend to attract plenty of attention that bids up their share prices,...
Exelixis, Inc. EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx (cabozantinib).The regulatory body approved Cabometyx for the treatment of adult and pediatric patients...
Shares of Exelixis, Inc. EXEL have risen 13.3% year to date compared with the industry’s growth of 6.6%. The stock has also outperformed the sector and the S&P 500 Index in this timeframe. The company's...
/CNW/ -- As the global cancer crisis intensifies, the demand for breakthrough treatments is reaching new heights. Statista data projects a 20% rise in annual...
For Immediate ReleaseChicago, IL – February 26, 2025 – Stocks in this week’s article are Gilead Sciences GILD, Exelixis EXEL, Synchrony Financial SYF and Molson Coors TAP.4 PEG-Based GARP Stocks...
The new year has been turbulent so far for the equity market, with geopolitical tensions and trade policies playing a significant role in shaping investor sentiment. Trump's tariff policies have not only...
Cancer drug specialist Exelixis (NASDAQ: EXEL) was quite the stock market star on Friday. Following news that it's making a big, shareholder-pleasing move, market players piled into the company to push...
From merger updates to earnings surprises, these healthcare stocks saw the biggest spike in Stocktwits chatter.
EXEL earnings call for the period ending December 31, 2024.
Exelixis reported increased revenue and earnings in Q4 2024, driven by strong cabozantinib sales, though competitive pressures and regulatory challenges remain.